pelabresib,hydroxyurea,ruxolitinib
novartis,constellation pharma,incyte
['mpnsm', 'manifest trial', 'hydroxyurea', '#mpn']
congress |#asco23 |francesco passamonti shared preliminary data from arm 4 of the manifest trial. pelabresib resulted in hematologic responses &amp; improved symptoms in pts with hr-et and r/r to hydroxyurea; it demonstrated a consistent safety profile to previous studies
#mpn #mpnsm 
Lifting levels of knowledge in myeloproliferative neoplasms (MPN). A global online platform providing latest treatment options and medical information #mpnsm